CureVac GmbH (CureVac)

Oncology Corporate Profile

HQ Location

Paul-Ehrlich-Str. 15
72076 Tubingen, Germany

Company Description

CureVac is the global leader in mRNA based vaccination technologies and develops mRNAbased vaccines as therapeutic vaccines in oncology as well as prophylactic vaccines for infectious diseases. The company has completed Phase I/IIa studies with cancer vaccines based on its RNActive® technology platform for the treatment of prostate cancer and nonsmall cell lung cancer (NSCLC). In addition, CureVac also independently develops RNActive® prophylactic vaccines against various infectious diseases. The company has also developed RNA-based adjuvants. Results with these CureVac products strongly suggest that they are safe and capable of inducing balanced immune responses including humoral and cellular, Th1 and Th2 and effector and memory responses.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CV9201immunotherapy1st line metastatic Non Small cell Lung Cancer (NSCLC)II
CV9103immunotherapyCastrate-resistant Prostate cancer (CRPC)II

View additional information on product candidates here »


Recent News Headlines

There are no news items to display